Sarah A. Solomon is a partner in the firm’s Technology & Life Sciences Group.

Ms. Solomon represents biotechnology, pharmaceutical, medical device, diagnostic and other life sciences companies in connection with their intellectual property, commercial and M&A transactions. She regularly advises private and public companies on complex strategic collaboration and partnering transactions (such as co-development, joint research and development agreements, patent licenses, strategic alliances and joint ventures); research, development and commercial relationships (such as manufacturing, distribution, supply, clinical trial, university licenses and services arrangements); and mergers and acquisitions (such as product acquisitions, spin-outs and patent portfolio acquisitions). Ms. Solomon also counsels clients in connection with international transactions and relationships in North America, South America, Europe and Asia.




Strategic Alliances and Collaborations

  • Moderna Therapeutics in strategic transactions with Merck, Alexion Pharmaceuticals and AstraZeneca with total upfront deal value in excess of $650 million, plus downstream payments; most recently, in its strategic collaboration with Merck for mRNA-based personalized cancer vaccines, with an upfront payment of $200 million
  • Blueprint Medicine in its worldwide collaboration with Roche for up to five small molecule kinase therapeutics for cancer immunotherapy; upfront of $45 million with total deal value of up to $965 million
  • ImmuNext in its exclusive, worldwide license with Sanofi to develop and commercialize a CD40L monoclonal antibody for use in autoimmune diseases, with potential deal value of up to $500 million, plus royalties
  • BlueRock Therapeutics, a next-generation regenerative medicine company, in its $225 million financing by Bayer and Versant Ventures and seminal in-licenses and alliances with Memorial Sloan Kettering, the Centre for Commercialization of Regenerative Medicine and University Health Networks
  • Teva in its license agreement with Heptares to develop and commercialize novel, small-molecule calcitonin gene-related peptide antagonists discovered by Heptares, valued up to $410 million, plus royalties
  • Cephalon in its exclusive license agreement with Eagle Pharmaceuticals with a total deal value in excess of $120 million, plus royalties
  • Surface Oncology in its strategic collaboration with Novartis to develop immunotherapeutics; up to $170 million in near-term cash payments, plus milestones and royalties
  • Unum Therapeutics in its strategic collaboration and license agreement with Seattle Genetics to develop and commercialize ACTR therapies for cancer, with a total potential deal value of over $640 million, plus royalties
  • Nogra Pharma in its $710 million global license agreement with Celgene for therapies to treat Crohn’s disease, with a total potential deal value up to $2.6 billion in milestones, plus royalties
  • Alnylam Pharmaceuticals in its transformational alliance with Genzyme for RNAi therapeutics as genetic medicines along with a $700 million equity investment


  • Nimbus in its sale of Nimbus Apollo and its Acetyl-CoA Carboxylase (ACC) inhibitor program to Gilead Sciences for $400 million and up to an additional $800 million in development milestone payments
  • Promedior in its exclusive purchase option agreement with Bristol-Myers Squibb with potential deal value up to $1.25 billion
  • F-star Alpha in its exclusive purchase option agreement with Bristol-Myers Squibb with potential deal value up to $475 million
  • TARIS Biomedical in the sale of its lead product LiRIS to Allergan for a total potential deal value in excess of $580 million
  • ZOLL Medical in its sale to Asahi Kasei for $2.2 billion

In The News







J.D., 2001
University of California Hastings College Law
B.S., Biology, 1996
University of California, San Diego



Get In Touch
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.


Search Other Lawyers